Pharmaceutical Dissolution Testing Services Market Size, Share | Report 2022-2030
The global pharmaceutical dissolution testing services market is expected to register significant growth in the forecast period. The major growth factor of the pharmaceutical dissolution testing services market are increasing demand for quality products due to awareness among consumers, rising technological advancements, and the production of a large number of drugs for various chronic diseases that have to undergo dissolution testing. The existence of strong regulatory procedures, such as USP (United States Pharmacopeia) and FDA, which demand rigorous testing criteria before permission can be granted, is also acting to promote the market for pharmaceutical dissolution testers on a global scale.
The COVID-19 pandemic has greatly impacted the pharmaceutical dissolution testing sector in addition to causing a global economic slowdown. The manufacture of unique and cutting-edge pharmaceuticals and biologic goods is increasing in response to the need to combat the pandemic, which is driving the rapid expansion of pharmaceutical dissolution testing services. Instrument monitoring, validation, maintenance, and possibly repair have seen an increase in acceptance and implementation.
In terms of dosage form, the capsule and tablet segments are expected to lead the market in the forecast period as they can be easily manufactured and in large quantities, they have high physical and chemical stability, and the amount of drug delivered to the body can be controlled, making them a popular choice among manufacturers.
The North America region is expected to dominate the market in the forecast period due to presence of major market players offering Pharmaceutical Dissolution Testing Services, the expansion of the healthcare infrastructure, the rise in disease burden, which will increase the demand for drugs that will in turn increase laboratory diagnostic testing, and the R&D expenditures made by market players for the creation of novel therapeutics for chronic diseases.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pharmaceutical Dissolution Testing Services Market
5.1. COVID-19 Landscape: Pharmaceutical Dissolution Testing Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pharmaceutical Dissolution Testing Services Market, By Method
8.1. Pharmaceutical Dissolution Testing Services Market, by Method, 2022-2030
8.1.1. In-vitro
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. In-vivo
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Pharmaceutical Dissolution Testing Services Market, By Dosage
9.1. Pharmaceutical Dissolution Testing Services Market, by Dosage, 2022-2030
9.1.1. Capsule
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Tablets
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Pharmaceutical Dissolution Testing Services Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Method (2017-2030)
10.1.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Method (2017-2030)
10.1.3.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Method (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Method (2017-2030)
10.2.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Method (2017-2030)
10.2.3.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Method (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Method (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Method (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Method (2017-2030)
10.3.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Method (2017-2030)
10.3.3.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Method (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Method (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Method (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Method (2017-2030)
10.4.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Method (2017-2030)
10.4.3.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Method (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Method (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Method (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Method (2017-2030)
10.5.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Method (2017-2030)
10.5.3.2. Market Revenue and Forecast, by Dosage (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Method (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Dosage (2017-2030)
Chapter 11. Company Profiles
11.1. Intertek Group Plc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Avivia BV
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Almac Group
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Agilent Technologies, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Catalent, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Thermofisher Scientific Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Cambrex
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Charles River laboratories
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Boston Analytical
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Pace Analytical Life Sciences
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers